assum coverag ew rate pt base
revis model estim summar statu
view key debat drive phiii gvhd
readout repres next key catalyst
also await dermatolog early-stag pipelin updat
base busi jakafi continu grow signific credit franchis
alreadi price oral inhibitor jakafi ruxolitinib lead
franchis approv blood cancer myelofibrosi mf polycthemia
vera pv well second-lin graft versu host diseas gvhd jakafi
gener sale manag guid peak sale
drug across mf pv gvhd believ jakafi
sale midpoint manag guidanc achiev consensu
estim current forecast peak sale upper bound manag
guidanc prior expir jakafi patent
result see limit room jakafi estim grow updat life
cycl extens program extend jakafi/mpn franchis beyond
late-stag readout oncolog dermatolog horizon
current level impli signific valu major program key late-stag
opportun pipelin jak inhibit gvhd ruxolitinib cream
dermatolog phiii data jakafi second-lin chronic gvhd phiii data
itacitinib first-lin acut gvhd expect two
dataset expect significantli greater investor focu itacitinib given
wholli own asset address larger market jakafi second-lin
set initi phiii data ruxolitinib cream expect believ
street anticip phiii itacitinib ruxolitinib cream studi
success forecast peak risk-adjust sale
itacitinib ruxolitinib cream respect believ broadli align
investor expect base pipelin valu impli current
share price said expect readout itacitinib
next key percept driver believ could face
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
volatil data depend specif data report
particularli regard clinic meaning
early-stag pipelin updat could impact valuat anticip
believ earlier-stag program could gener investor
assess pemigatinib anticip bladder cancer data well
possibl tumor agnost data jakafi life cycl extens effort
also expect updat begin phii dataset
program also expect overal given signific credit
 jakafi late-stag pipelin alreadi factor estim
equal-weight head phiii gvhd dermatolog data await
early-stag pipelin updat believ could critic
impact investor percept pipelin option tail busi
beyond jakafi patent expir
jakafi perform oncolog dermatolog pipelin readout drive
jakafi perform oncolog dermatolog pipelin readout drive
deriv price target discount cash flow analysi
factor explicit revenu project use
discount rate termin growth rate
jakafi sale upper rang long-term guidanc clear blockbust
perform key late-stag pipelin asset strong contribut
early-stag pipelin jakafi sale peak total revenu
itacitinib first-lin gvhd gener peak sale
ruxolitinib cream gener peak sale across vitiligo atop
dermat early-stag pipelin contribut aggreg peak sale
jakafi sale midpoint long-term guidanc coupl strong
pipelin realiz jakafi sale manag long-term
guidanc peak total revenu approv
strong uptak late-stag pipelin asset itacitinib first-lin gvhd peak
sale ruxolitinib cream vitiligo atop dermat
aggreg peak sale aggreg peak sale
early-stag pipelin
jakafi sale manag guidanc modest royalti revenu
minim pipelin success jakafi sale peak royalti revenu
jakafi ex-u olumi peak iclusig sale
aggreg peak pipelin revenu
jakafi base busi room
grow hold right jakafi
ruxolitinib ex-u right held
novarti jakafi sale
grown y/i
y/i forecast
continu growth jakafi
meaning contribut label
expans graft versu host diseas
gvhd forecast peak jakafi sale
roughli midpoint
manag long-term guidanc
prior jakafi patent expir
pipelin effort come focu
late throughout
develop broad multi-asset pipelin
believ key area investor focu
phiii asset itacitinib gvhd
ruxolitinib cream vitiligo atop
effort fgfr inhibitor pemigatinib
first phiii readout itacitinib first-lin
gvhd expect first set
phiii ruxolitinib cream data expect
adjust sale itactinib
gvhd ruxolitinib cream
jakafi life cycl extens effort
pemigatinib bladder cancer also
expect
factor grow jakafi sale base
strong contribut late-stag
pipelin result find current
risk/reward valuat balanc
phiii data jakafi itacitinib gvhd
phiii data ruxolitinib cream atop
data pemigatinib bladder cancer
tumor agnost program
addit detail jakafi life cycl
phiii data jakafi steroid-refractori
chronic gvhd studi
phiii data itacitinib steroid-na acut
gvhd studi
full phii data pemigatinib second-lin
cholangiocarcinoma cca cca
nda submiss expect
phiii data ruxolitinib cream atop
dermat
phii data inhibitor parsaclisib
phii data antibodi
updat jakafi life cycl extens
program
risk achiev price
 jakafi sale perform
poor phiii result itacitinib and/or
ruxolitinib cream either due outright safeti
and/or efficaci failur due result
clinic meaning
failur and/or minim success early-
stage pipelin asset
assum coverag equal-weight rate price target
biotechnolog compani focus primarili oncolog dermatolog
partnership novarti commerci oral inhibitor jakafi ruxolitinib
blood cancer myelofibrosi mf polycythemia vera pv second-
line acut graft versu host diseas gvhd record jakafi sale receiv
royalti novarti commerci ex-u jakafi gener sale
manag guid sale long-term peak
sale guidanc beyond jakafi incyt earn royalti sale jak
inhibitor olumi baricitinib commerci lilli cover david rising
develop broad pipelin dermatolog oncolog asset late-stag
pipelin asset includ inhibitor itacitinib gvhd ruxolitinib cream atop
dermat vitiligo fgfr inhibitor pemigatinib oncolog earlier stage asset
includ inhibitor parsaclisib antibodi jakafi life cycl
extens program intend potenti extend jakafi/mpn franchis beyond
expir jakafi patent outlin key factor drive rate
price target
jakafi durabl asset room grow consensu current appear factor
long-term sale near upper end manag guidanc manag
guid peak jakafi sale reflect three indic mf pv
gvhd believ peak sale within rang achiev yearli jakafi
sale estim larg line consensu
grow conserv vs consensu jakafi lose patent
protect peak sale estim fall near midpoint
manag long-term guidanc wherea consensu model peak sale
upper bound manag guidanc street fulli valu jakafi across
mf pv gvhd see littl room increas estim investor
sentiment regard jakafi manag abl provid updat early-stag
jakafi life cycl extens program could extend jakafi franchis beyond
expect initi updat program throughout
exhibit consensu morgan stanley research jakafi sale estim
numer pivot readout near-mid term current valuat impli
signific valu late-stag pipelin manag guid two phiii
readout gvhd one jakafi second-lin chronic gvhd
second itacitinib first-lin acut gvhd expect significantli investor
focu itactinib readout repres larger opportun incyt
own global right base data gener date jakafi itacitinib
gvhd believ investor expect studi readout posit manag
also guid full pivot phii cca data pemigatinib initi data
alreadi releas well nda submiss cca given
rel small address market cca expect signific investor
attent pemigatinib expect data bladder cancer
possibl tumor agnost program ruxolitinib cream phiii data atop
dermat expect would expect phiii vitiligo data late
current forecast peak risk-adjust sale itacitinib ruxolitinib cream
respect believ loos line investor
expect await granular phiii data refin view
program earlier stage program antibodi
await initi data
primari complet atop dermat vitiligo studi respect per clinicaltri gov
overal estim assign signific credit jakafi late-stag pipelin
asset ruxolitinib cream itacitinib equal-weight await phiii data
compound late wait obtain clariti throughout
earlier-stag pipelin asset parsaclisib jakafi life cycl
extens program could inflect pipelin valu impact tail jakafi/mpn
franchis valu help frame view valuat provid sotp analysi
along illustr key driver bear-to-bas base-to-bul case
valuat driver net refer pemigatinib parsaclisib capmatinib
pemigatinib addit early-stag pipelin corporate/oth spend
probabl success
value-per-share valuat
exhibit incyt bear case base case valuat bridg
exhibit incyt base bull valuat bridg
usd million
present valu
discount
price target includ risk-adjust revenu
deriv price target discount cash flow dcf analysi use discount
rate termin growth rate
valuat methodolog prefer use dcf analysi valu biotechnolog
compani believ dcf fulli captur up-front invest period well
long-term earn potenti pipelin asset investor look
biotechnolog multipl basi price-to-earnings prefer dcf rigor
requir explicit assumpt long-term prospect compani
discount rate util discount rate compani
commerci asset jakafi earn royalti anoth commerci drug
olumi coverag util discount rate commerci compani
rate compani random phii data rate
termin growth rate model explicit revenu assum
termin growth rate onward
revenu forecast revenu jakafi myeloprolif neoplasm mpn
graft versu host diseas gvhd also model royalti sale
olumi commerci lilli cover david rising addit forecast
risk-adjust sale pipelin program itacitinib gvhd pemigatinib
cholangiocarcinoma bladder cancer ruxolitinib cream vitiligo atop dermat
iclusig parsaclisib follicular lymphoma capmatinib royalti non-smal cell
lung cancer lastli includ aggreg sale earlier stage pipelin program
estim total sale grow
econom partner novarti jakafi capmatinib lilli
olumi takeda iclusig econom partnership
factor dcf
cog estim cog grow
percentag product sale forecast cog stay constant
oper expens project oper expens sg
grow gradual oper expens growth stem fund
late-stag develop program commerci effort
risk price target includ jakafi sale perform
expect poor phiii result itacitinib and/or ruxolitinib cream either due
outright safeti and/or efficaci failur due result clinic
meaning failur and/or minim success early-stag pipelin asset
program
lead franchis inhibitor jakafi ruxolitinib gener
 sale repres compani total revenu jakafi
approv treat blood cancer myelofibrosi mf polycythemia vera pv
also recent obtain approv treat steroid refractori acut graft versu host
diseas sr agvhd complic often aris patient undergo allogen
stem cell transplant jakafi also evalu phiii studi steroid
refractori chronic gvhd sr cgvhd data expect hold
right jakafi partner novarti hold ex-u right across mf pv gvhd
manag guid aggreg peak sale jakafi beyond
jakafi manag develop broad pipelin therapeut candid within
oncolog dermatolog variou stage develop tabl provid
summari pipelin statu key studi readout
exhibit summari incyt pipelin catalyst
primari complet atop dermat vitiligo studi respect per clinicaltri gov
pipelin perspect believ key area investor focu current
progress late-stag program itacitinib gvhd ruxolitinib cream atop
dermat ad vitiligo molecul gener encourag data date
target larg address patient segment unmet need believ
fgfr inhibitor pemigatinib could receiv investor attent come month
first nda submiss molecul near cholangiocarcinoma cca cancer
bile duct expect focu molecul matur data
becom avail bladder cancer tumor agnost studi
dataset could potenti lead larger indic expect data
studi lastli believ compani effort jakafi life cycl
extens strategi addit investor focu patent jakafi expir
manag note work underway extend releas
formul combin approach extend jakafi franchis beyond
briefli summar current statu view topic also
provid overview revis model sum-of-the-part analysi
area investor focu
ruxolitinib cream dermatolog
develop ruxolitinib cream atop dermat ad vitiligo unlik oral
ruxolitinib jakafi partner novarti own global right
ruxolitinib cream phiii studi ad current
enrol patient anticip primari complet august phiii
studi vitiligo recent initi primari complet
expect april expect data ad program
vitiligo program late
phiii ad program evalu two concentr ruxolitinib cream
topic use vs vehicl cream adolesc adult mild-to-moder
atop dermat two ident design phiii studi enrol
patient primari endpoint studi proport patient achiev
investig global assess iga score grade improv
baselin key secondari endpoint includ proport patient achiev
proport patient achiev point improv itch
numer rate scale nr score nr itch sever itch
phii data ruxolitinib cream ad present recent
world congress dermatolog wcd june phii studi enrol similar
patient popul phiii studi underway primari endpoint mean
chang baselin easi score week ruxolitinib cream cohort
secondari endpoint iga easi respond rate itch nr score safeti
phii studi involv double-blind treatment period investig variou
concentr ruxolitinib cream follow open-label period
patient treat cream safeti follow-up period
exhibit phii studi design overview ruxolitinib cream atop dermat
efficaci safeti data ruxolitinib cream adult patient atop dermat result phase studi raoof et al
world congress dermatolog
compar topic steroid ruxolitinib cream demonstr noninferior
week two four primari endpoint notabl numer superior
ruxolitinib cream week two week addit improv
baselin easi score cream statist signific vs vehicl
cream week two four eight first four week itch score decreas
notabl ruxolitinib cream vs steroid vehicl cream transit
patient ruxolitinib cream week eight also associ notabl
improv easi score proport patient iga respons lastli
cream appear safe seriou teae discontinu due teae
exhibit improv easi score phii studi rux cream
exhibit proport patient iga respons phii studi
rux cream ad
efficaci safeti data ruxolitinib cream adult patient atop dermat
result phase studi raoof et al world congress dermatolog
efficaci safeti data ruxolitinib cream adult patient atop dermat
result phase studi raoof et al world congress dermatolog
overal believ phii data bode well ruxolitinib cream abil demonstr
compel efficaci safeti profil phiii program underway result
assign probabl success ruxolitinib cream ad forecast
peak risk-adjust sale cream across base peak
penetr overal ad popul geographi acknowledg
ruxolitinib cream need secur premium price order meaning sale
driver believ price achiev phiii data replic phii
efficaci profil clean safeti profil bear may point slow
launch eucrisa nonsteroid topic inhibitor approv ad
challeng proxi ruxolitinib cream note eucrisa uptak like
hinder burn sensat report certain patient upon applic
ae report ruxolitinib cream phii ad studi await phiii data
close monitor signal
preval ad
patient mild ad
patient mild ad
patient ruxolitinib cream
 ad patient treat
preval ad
patient mild ad
patient mild ad
patient ruxolitinib cream
ad patient treat
row revenu
probabl success
phiii program vitiligo initi recent follow present phii
data wcd two phiii vitiligo studi enrol patient
evalu ruxolitinib cream vs vehicl cream week
patient receiv ruxolitinib cream extens period primari
endpoint phiii studi proport patient achiev
improv face vitiligo area week key
secondari endpoint includ chang facial bodi surfac area f-bsa week
proport patient achiev week proport patient
achiev week phii studi evalu variou concentr
ruxolitinib cream alongsid vehicl cream week re-random
patient anoth period follow open-label period
exhibit phii studi design overview ruxolitinib cream vitiligo
efficaci safeti ruxolitinib cream treatment vitiligo result random double-blind dose-rang vehicle-
control studi rosmarin et al world congress dermatolog
week respons concentr ruxolitinib cream
achiev statist signific vs vehicl greatest differenti
demonstr qd bid cohort week primari
endpoint phiii program strongest respons observ bid
cohort respond bid ruxolitinib cream vs vehicl cream
ruxolitinib cream gener well toler phii program seriou
treatment-rel common observ acn applic site
pruritu viral upper respiratori tract infect headach notabl
imbal vehicl cohort ruxolitinib cream cohort except acn
continu monitor phii data eventu
exhibit respons phii studi rux cream vitiligo
exhibit respons phii studi rux cream vitiligo
efficaci safeti ruxolitinib cream treatment vitiligo result
random double-blind dose-rang vehicle-control studi rosmarin et al world congress
efficaci safeti ruxolitinib cream treatment vitiligo result
random double-blind dose-rang vehicle-control studi rosmarin et al world congress
base phii data gener date current statu develop
assign vitiligo program probabl success po estim peak risk-
adjust sale row assum partner
ruxolitinib cream earn royalti estim impli peak uptak vitiligo
patient
preval vitiligo
patient ruxolitinib cream
 vitiligo patient treat
preval vitiligo
patient ruxolitinib cream
eu vitiligo patient treat
preval vitiligo
patient ruxolitinib cream
japan vitiligo patient treat
probabl success
risk-adjust royalti revenu japan
total risk-adjust vitiligo revenu
overal believ phii data ruxolitinib cream ad vitiligo highli
encourag estim two indic aggreg present risk-
adjust peak sale opportun given unmet need indic safe
effect nonsteroid topic ad await data vitiligo expect
ruxolitinib cream data late also await phii vitiligo data
oral compound expect base
decemb primari complet phii studi underway understand
impact potenti compet molecul may vitiligo treatment
paradigm come year
jak inhibit graft versu host diseas
graft versu host diseas gvhd common complic allogen stem cell
transplant asct techniqu often employ treatment option blood
cancer gvhd t-cell donor transplant attack healthi cell
transplant recipi gvhd present differ way across differ patient
condit gener categor either acut gvhd agvhd chronic gvhd
cgvhd agvhd typic present within day transplant wherea cgvhd
occur point follow transplant addit agvhd observ
primarili impact skin liver gi tract wherea symptom cgvhd
widespread affect eye mouth skin gi tract lung joint
among area bodi patient cgvhd last mani year
review literatur suggest asct patient develop agvhd
agvhd patient sr agvhd patient progress cgvhd
wide varieti drug use help prevent gvhd includ calcineurin
inhibitor chemotherapi standard care gvhd occur oral
steroid howev patient becom steroid refractori sr steroid
use lead numer side effect increas infect risk need
addit treatment option gvhd patient develop jakafi
inhibitor ruxolitinib sr second-lin acut chronic gvhd inhibitor
itactinib steroid nave first-lin acut chronic gvhd statu
program summar
exhibit statu jakafi itacitinib gvhd
partner
fulli own incyt
approv
data allow eu file jakafi approv sr agvhd base
initi januari anticip primari complet date august
jakafi approv sr agvhd may base data single-
arm studi jakafi steroid led orr cr rate pr
rate sr patient phiii studi data expect
evalu jakafi vs best avail therapi bat select investig sr
agvhd expect limit investor focu given primari purpos
dataset enabl novarti file jakafi sr agvhd ex-u consensu
assum posit data base result phiii studi
evalu jakafi vs bat sr cgvhd data studi also expect
posit data import establish jakafi standard
treatment option sr diseas given multipl therapi use current
includ ibrutinib tacrolimu infliximab among other defin standard
expect less focu readout compar phiii studi
itacitinib expect first-lin acut set given rel modest
 revenu opportun jakafi sr cgvhd vs itacitinib first-lin acut
set non risk-adjust basi forecast peak sale jakafi
sr cgvhd itacitinib sn agvhd greater global
opportun itacitinib present own ww right itactinib right
jakafi
enrol patient evalu itacitinib steroid vs
placebo steroid first-lin treatment primari endpoint orr day
key secondari endpoint includ nonrelaps mortal month dor proof-of-
concept itacitinib first-lin agvhd treatment establish dataset
present summar data reflect
dose use studi
exhibit proof-of-concept phi data itacitinib gvhd
manag note power demonstr orr
benefit rel reduct nonrelaps mortal believ orr
nonrelaps mortal benefit phiii studi achiev base phi data
although acknowledg phi data small number patient account
remain develop risk phiii studi assign itacitinib po
risk-adjust basi estim peak global sale itacitinib
gvhd expect investor focu increas throughout
phiii readout approach believ dataset next major
percept driver consensu anticip posit readout
expect could face volatil depend
specif data
patient acut gvhd
patient acut gvhd
agvhd patient treat
agvhd patient treat
patient steroid administ itacitinib
patient steroid administ itactinib
patient steroid administ itacitinib
patient steroid administ itacitinib
patient acut gvhd
patient acut gvhd
agvhd patient treat
agvhd patient treat
patient steroid administ itacitinib
patient steroid administ itactinib
patient steroid administ itacitinib
patient steroid administ itacitinib
hold right jakafi ruxolitinib myeloprolif neoplasm mpn
includ mf pv gvhd wherea novarti hold ex-u right jakafi
indic jakafi sale estim
 jakafi sale near upper end manag guidanc
long-term manag guid peak jakafi sale includ
mf pv gvhd jakafi recent approv steroid-refractori acut
set believ peak jakafi sale within midpoint compani long-
term guidanc achiev estim peak sale prior
expir jakafi patent point anticip rapid sale
 jakafi sale repres bulk compani revenu base total
revenu given larger late-stag develop opportun
ruxolitinib cream itacitinib could replac potenti lost revenu follow
jakafi ip expir year away potenti commerci still hold
develop regulatori risk mani investor understand interest life
cycl manag strategi could extend jakafi franchis beyond
three approach manag allud includ new long-act
formul may allow qd daili dose jakafi current indic
bid twice daili dose mf pv gvhd target discoveri beyond jak inhibit
mpn jakafi combin improv safety/efficaci profil jakafi
monotherapi particularli sub-optimal respond
manag note long-act ruxolitinib current formul stage
ind file follow complet formul work manag
indic long-act jakafi could clinic studi data
potenti advanc combin jakafi initi
phii data present mf patient sub-optimal respons loss
respons follow month jakafi monotherapi earli data indic
combin jakafi molecul associ
reduct spleen volum improv mf symptom report
patient addit seriou treatment-rel report indic
dose strategi util studi qd follow qw dose may
help mitig toxic would expect addit jakafi
combin data along updat progress jakafi pim
understand potenti valu jakafi extens beyond conduct
scenario analysi evalu per share valu life cycl extens strategi
abl maintain peak jakafi sale
demonstr everi peak sale estim
maintain worth estim estim
scenario peak jakafi sale maintain
could potenti worth await greater granular jakafi
life cycl extens effort
progress fgfr inhibitor pemigatinib four differ indic
cholangiocarcinoma cca cancer bile duct bladder cancer mpn
driven chromosom transloc tumor agnost
advanc program cca pivot studi cca
complet nda submiss expect interim
data present esmo updat data made
avail full data form basi cca nda
submiss patient metastatic/surg unresect cca
fail prior line therapi possess fgf/fgfr alter primari endpoint
orr cohort interim updat esmo demonstr
cohort cohort patient month follow-up
transloc orr pr median month
median os month cohort patient fgf/fgfr
alter cohort respect orr median month
median os month efficaci data indic pemigatinib highli
select driven cca common teae
hypophosphatemia hyponatremia abdomin pain arthralgia comparison
earli data set challeng loos comparison interim data vs
recent data competitor indic pemigatinib efficaci profil highli
competit given encourag data gener date current unmet need
cca believ pemigatinib could achiev peak share address
patient across geographi full data matur well appear line
interim updat base current avail data revenu model
forecast pemigatinib cca achiev peak risk-adjust global
sale recent initi phiii studi pemigatinib cca primari
complet anticip earli acknowledg posit data set
could broaden use pemigatinib cca beyond base case estim await
initi data pemigatinib competitor cca prior assign greater valu
indic
incid intrahepat cholangiocarcinoma icca
incid rate intrahepat cholangiocarcinoma icca
icca incid relat mutat
icca incid relat mutat
 icca patient pemigatinib
total incid icca
icca case cca
icca incid relat mutat
icca incid relat mutat
eu icca patient pemigatinib
incid cca
incid rate cca
japan incid icca
icca case cca
icca incid relat mutat
icca incid relat mutat
japan icca patient pemigatinib
probabl success
recent updat pemigatinib bladder cancer provid esmo
poster present phii studi evalu pemigatinib
patient metastat surgic unresect bladder cancer fgf/fgfr
alter cohort studi includ patient mutations/fus
cohort includ patient fgf/fgfr alter orr cohort
pr median dor month median month
orr cohort median month indic
pemigatinib select driven bladder cancer cohort patient
pericardi effus increas blood creatinin phlebiti
present note dose amend move forward
continu dose schedul vs intermitt schedul previous follow
patient follow week week schedul data continu dose
schedul allow accur comparison pemigatinib
pivot data fgfr inhibitor balversa erdafitinib cover david
lewi balversa approv april bladder cancer pivot studi
balversa employ continu dose schedul recruit
expect complet would expect full data program
data posit manag expect file snda pemigatinib
bladder cancer believ bar success pemigatinib bladder
cancer efficaci line greater balversa differenti safeti
profil particularli ocular safeti balversa label note central serou
retinopathy/retin pigment epitheli detach csr/rped report
patient treat balversa result label guid monthli
ophthalmolog test first four month treatment everi quarter
thereaft also begun phii studi pemigatinib
metastatic/unresect bladder cancer primari complet anticip late
acknowledg larg potenti address patient group repres
driven bladder cancer manag estim patient across
 eu japan given earli natur pemigatinib data competit
space current model penetr yearli incid
mutat metastatic/unresect urotheli carcinoma conserv combin
po lead peak risk-adjust sale although
acknowledg upsid estim possibl data
bladder cancer data pemigatinib achiev signific differenti compet
 bladder cancer incid treat
bladder cancer incid treat
incid metastatic/unresect uc
incid metastatic/unresect uc
incid mutat
incid mutat
 bladder cancer patient pemigatinib
incid metastatic/unresect uc
incid metastatic/unresect uc
incid mutat
incid mutat
eu bladder cancer patient pemigatinib
incid metastatic/unresect uc
incid metastatic/unresect uc
incid mutat
incid mutat
japan bladder cancer patient pemigatinib
japan bladder cancer incid treat
probabl success
addit bladder cancer expect phii tumor agnost program
gener investor interest data becom avail studi current
recruit patient anticip primari complet decemb
would expect initi data overal believ consensu expect posit full
data cca on-schedul cca nda submiss result
believ next key catalyst pemigatinib data bladder cancer
potenti tumor agnost program
tabl summar key compon dcf valuat current
valu jakafi mpn gvhd itacitinib gvhd pemigatinib cca bladder cancer
ruxolitinib cream ad vitiligo royalti olumi rheumatoid arthriti ra
parsaclisib follicular lymphoma fl iclusig capmatinib royalti non-smal cell
lung cancer nsclc everi develop stage product assign risk-adjust
revenu project base data gener date view
rel risk program abil obtain regulatori approv addit explicit
revenu project market product mid/late-stag pipelin program
dcf account earlier-stag pipelin program includ antibodi
addit indic among other broader aggreg
pipelin revenu estim overal largest contributor base case valuat
 jakafi sale ruxolitinib cream aggreg early-stag pipelin
probabl success
value-per-share valuat
mileston contract revenu
cost expens
product revenu incl definite-liv intang amort
chang fair valu acquisition-rel conting consider
total cost expens
incom loss oper
unreal loss long-term invest
expens relat senior note convers
incom loss provis incom tax
provis incom tax
share use comput net incom loss per share
exhibit revenu incyt
royalti ex-u sale
royalti eu sale
royalti row sale
royalti row sale
royalti ww sale
royalti ww sale
revenu royalti
cash equival
prepaid expens current asset
restrict cash invest
properti equip net
accru current liabil
accumul comprehens incom
total liabil stockhold equiti
flow oper activ
in-process research develop
expens relat senior note convers
unreal loss long-term invest
chang fair valu acquisition-rel conting consider
chang oper asset liabil
prepaid expens asset
accru liabil
net cash provid use oper activ
flow invest activ
acquisit busi net cash acquir
purchas long-term invest
purchas market secur
sale matur market secur
net cash use invest activ
flow financ activ
proce issuanc common stock stock plan
proce issuanc common stock net
paid connect senior note convers
payment conting consider
net cash provid financ activ
effect exchang rate cash cash equival restrict cash invest
net increas cash cash equival restrict cash invest
cash equival restrict cash invest begin period
cash equival restrict cash invest end period
